PSORS11
MCID: PSR032
MIFTS: 47

Psoriasis 11 (PSORS11)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Psoriasis 11

MalaCards integrated aliases for Psoriasis 11:

Name: Psoriasis 11 57 12 72 15
Psors11 57 12 72
Psoriasis 11, Susceptibility to 57 29
Psoriasis Susceptibility 11 57 13
Psoriasis Vulgaris 72 70
Psoriasis 72 70
Pv 72

Classifications:



External Ids:

Disease Ontology 12 DOID:0111285
OMIM® 57 612599
OMIM Phenotypic Series 57 PS177900
MeSH 44 D011565
MedGen 41 C2675475
UMLS 70 C0033860 C0263361

Summaries for Psoriasis 11

UniProtKB/Swiss-Prot : 72 Psoriasis 11: A common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis.

MalaCards based summary : Psoriasis 11, also known as psors11, is related to spondyloarthropathy 1 and spondylitis, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Psoriasis 11 is PSORS11 (Psoriasis Susceptibility 11), and among its related pathways/superpathways are Th17 cell differentiation and Immune response IL-23 signaling pathway. The drugs Metformin and Esomeprazole have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and endothelial.

Disease Ontology : 12 A psoriasis that has material basis in variation in a region on chromosome 5q31.1-q33.1 that includes IL12B.

More information from OMIM: 612599 PS177900

Related Diseases for Psoriasis 11

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13 Psoriasis 15

Diseases related to Psoriasis 11 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1250)
# Related Disease Score Top Affiliating Genes
1 spondyloarthropathy 1 31.0 IL23R IL17A
2 spondylitis 30.5 IL23R IL17A
3 psoriasis 30.5 PSORS11 IL23R IL17A IL12B
4 autoimmune disease 30.4 IL23R IL17A IL12B
5 nail disease 30.3 IL23R IL17A
6 leprosy 3 29.9 IL23R IL17A
7 celiac disease 1 29.6 YDJC IL23R IL17A
8 panuveitis 29.4 IL23R IL17A
9 relapsing-remitting multiple sclerosis 29.1 IL23R IL17A
10 vogt-koyanagi-harada disease 29.1 IL23R IL17A
11 chagas disease 29.0 IL17A IL12B
12 lyme disease 28.8 IL23R IL17A
13 psoriasis 14, pustular 11.9
14 pustulosis of palm and sole 11.9
15 psoriatic arthritis 11.7
16 psoriasis 1 11.7
17 pustular psoriasis 11.7
18 psoriasis 13 11.6
19 guttate psoriasis 11.6
20 psoriasis 2 11.5
21 psoriasis 7 11.5
22 psoriasis 15, pustular 11.4
23 pustulosis palmaris et plantaris 11.4
24 psoriasis 4 11.4
25 psoriasis 3 11.4
26 psoriasis 6 11.4
27 psoriasis 10 11.4
28 psoriasis 5 11.4
29 psoriasis 12 11.4
30 psoriasis 8 11.4
31 psoriasis 9 11.4
32 psoriatic juvenile idiopathic arthritis 11.4
33 psoriasis 15 11.3
34 tranebjaerg svejgaard syndrome 11.2
35 skin disease 11.2
36 arthritis 11.2
37 juvenile rheumatoid arthritis 11.1
38 mental retardation and psoriasis 11.1
39 impetigo herpetiformis 11.1
40 geographic tongue 11.0
41 vitiligo-associated multiple autoimmune disease susceptibility 1 11.0
42 parapsoriasis 11.0
43 singleton-merten syndrome 1 11.0
44 rheumatoid factor-negative juvenile idiopathic arthritis 11.0
45 systemic onset juvenile idiopathic arthritis 11.0
46 dermatitis 10.9
47 dermatitis, atopic 10.9
48 subacute cutaneous lupus erythematosus 10.9
49 singleton-merten syndrome 10.8
50 temporomandibular ankylosis 10.8

Graphical network of the top 20 diseases related to Psoriasis 11:



Diseases related to Psoriasis 11

Symptoms & Phenotypes for Psoriasis 11

Clinical features from OMIM®:

612599 (Updated 05-Apr-2021)

UMLS symptoms related to Psoriasis 11:


pruritus; exanthema; psoriasiform rash

Drugs & Therapeutics for Psoriasis 11

Drugs for Psoriasis 11 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 4091 14219
2
Esomeprazole Approved, Investigational Phase 4 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
3
Desonide Approved, Investigational Phase 4 638-94-8 5311066
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
5
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
6
Sodium citrate Approved, Investigational Phase 4 68-04-2
7
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
9
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
10
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
11
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
12
Desoximetasone Approved Phase 4 382-67-2 5311067
13
Clocortolone Approved Phase 4 34097-16-0, 4828-27-7 5311052 5282493
14
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
15
Zinc Approved, Investigational Phase 4 7440-66-6 32051
16
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
17
Ustekinumab Approved, Investigational Phase 4 815610-63-0
18
Ixekizumab Approved, Investigational Phase 4 1143503-69-8
19
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
20
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
21
Vedolizumab Approved Phase 4 943609-66-3
22
Alefacept Approved, Investigational, Withdrawn Phase 4 222535-22-0
23
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
24
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
25
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
26
Capsaicin Approved Phase 4 404-86-4 1548943
27
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
29
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
30
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
31
Trichostatin A Experimental Phase 4 58880-19-6
32 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
33 Citrate Phase 4
34 Anticoagulants Phase 4
35 diuretics Phase 4
36 Chelating Agents Phase 4
37 Hydrocortisone hemisuccinate Phase 4
38 Hydrocortisone 17-butyrate 21-propionate Phase 4
39 Vitamin B9 Phase 4
40 Folic Acid Antagonists Phase 4
41 Vitamin B Complex Phase 4
42 Folate Phase 4
43 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
44 Myeloma Proteins Phase 4
45 Paraproteins Phase 4
46 Hydrocortisone-17-butyrate Phase 4
47 Bronchodilator Agents Phase 4
48 Anti-Allergic Agents Phase 4
49 Tin Fluorides Phase 4
50 Clocortolone pivalate Phase 4

Interventional clinical trials:

(show top 50) (show all 1488)
# Name Status NCT ID Phase Drugs
1 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
2 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
3 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
4 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
5 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
6 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
7 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
8 Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism: A Double-Blind, Randomized, Placebo-Controlled Study Unknown status NCT03629639 Phase 4 Metformin
9 A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis Unknown status NCT03408756 Phase 4 methotrexate
10 Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis Unknown status NCT02829424 Phase 4 Methotrexate;Methotrexate Placebo
11 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
12 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
13 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
14 A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis Unknown status NCT03553433 Phase 4 Apremilast 30mg;Placebo Oral Tablet
15 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
16 An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab Unknown status NCT03827876 Phase 4 Enstilar 0.005%-0.064% Topical Foam
17 A Single Center Study to Evaluate the Effectiveness and Safety of Add on Enstilar® in Patients Using OTEZLA® for Moderate to Severe Plaque Psoriasis Unknown status NCT03587194 Phase 4 Otezla
18 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
19 Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis Unknown status NCT03453190 Phase 4
20 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
21 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
22 Studying the Effect of Methotrexate Alone Versus Methotrexate and Vitamin D on the Cardiovascular Risk of Psoriatic Patients Unknown status NCT03904680 Phase 4 Methotrexate;Vitamin D
23 Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis Completed NCT03348462 Phase 4 ethosomal preparation of anthralin;liposomal preparation of anthralin
24 Can an App Supporting Psoriasis Patients Improve Adherence to Topical Treatment? A Single-blind Randomized Controlled Trial Completed NCT02858713 Phase 4 Calcipotriene + Betamethasone Dipropionate
25 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
26 Energy-restricted, n-3 Polysaturated Fatty Acids-rich Diet Improves the Clinical Response to Immuno-modulating Drugs in Obese Patients With Plaque-type Psoriasis: a Randomized Control Clinical Trial. Completed NCT01876875 Phase 4
27 A Preliminary, Open Label, Single-arm Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy Completed NCT01761019 Phase 4 Taclonex Topical Suspension
28 Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea Completed NCT01181570 Phase 4 Adalimumab;Placebo
29 Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab Completed NCT00967538 Phase 4 etanercept 50 mg
30 An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept Completed NCT00493324 Phase 4 alefacept;polyvalent pneumococcal vaccine
31 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Explore Changes in Subcutaneous Adipose Tissue and Modulation of Skin Inflammation After 12 Weeks of Treatment With Secukinumab, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis Completed NCT03055494 Phase 4
32 Enbrel® in Psoriatic Arthritis Completed NCT00111124 Phase 4 Enbrel®
33 A Multicenter, Open-Label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL(r) in Combination With Narrowband UVB Phototherapy for the Treatment of Psoriasis Completed NCT00110981 Phase 4 Etanerept;Etanercept
34 An Investigator-Initiated, Assessor Blinded, Randomized Study Comparing the Mechanism of Action of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis. Completed NCT00932113 Phase 4 Methotrexate;Adalimumab (Humira)
35 An Open Label, Prospective Cohort Pilot Study to Evaluate the Efficacy and Safety of Etanercept in the Treatment of Moderate to Severe Plaque Psoriasis in Patients Who Have Not Had an Adequate Response to Adalimumab Completed NCT00833729 Phase 4 etanercept
36 Pilot Study on the Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis Completed NCT00940862 Phase 4
37 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Secukinumab on Aortic Vascular Inflammation and Cardiometabolic Biomarkers After 12 Weeks of Treatment, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completed NCT02690701 Phase 4 Secukinumab 300 mg
38 A Double-blinded, Placebo-controlled Study to Evaluate the Tolerability and Efficacy of Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color Completed NCT03506477 Phase 4 Enstilar® foam;Vehicle foam
39 A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Completed NCT03331835 Phase 4 Fumaric acid esters
40 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
41 A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris Completed NCT00248456 Phase 4 Calcipotriol plus betamethasone dipropionate ointment
42 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. Completed NCT02733874 Phase 4 Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
43 Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris Completed NCT00216892 Phase 4 Calcipotriol, (calcipotriol + betamethasone)
44 A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris Completed NCT00640393 Phase 4 Etanercept
45 Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris Completed NCT01707043 Phase 4 Taclonex
46 Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris Completed NCT02004574 Phase 4 Calcipotriol/betamethasone dipropionate gel
47 Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Completed NCT02533973 Phase 4 Xamiol® gel;Daivonex® scalp solution
48 A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis Completed NCT02125279 Phase 4 Calcitriol
49 A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis Completed NCT03942042 Phase 4 Ixekizumab
50 Randomised, Open-label Preliminary Study to Assess the Effects of 2 Regimens of Etanercept on Nail and Skin Symptoms in Patients With Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept

Search NIH Clinical Center for Psoriasis 11

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Acitretin
alefacept
Aloe vera preparation
Anthralin
ANTHRALIN PWDR
Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
calcipotriene
Calcitriol
Cholecalciferol
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Cod Liver Oil
Colloid sulfur
Cyclosporine
Etretinate
Fish Liver Oils
fluocinolone
Fluocinolone Acetonide
hydroxyurea
Methotrexate
Methotrexate Sodium
Methoxsalen
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Thioguanine
Trioxsalen

Genetic Tests for Psoriasis 11

Genetic tests related to Psoriasis 11:

# Genetic test Affiliating Genes
1 Psoriasis 11, Susceptibility to 29

Anatomical Context for Psoriasis 11

MalaCards organs/tissues related to Psoriasis 11:

40
Skin, Liver, Endothelial, T Cells, Bone, Pituitary, Monocytes

Publications for Psoriasis 11

Articles related to Psoriasis 11:

(show all 20)
# Title Authors PMID Year
1
Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. 57
19169255 2009
2
Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. 57
18800148 2009
3
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. 57
19169254 2009
4
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. 57
17587057 2007
5
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. 57
17236132 2007
6
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. 57
15610511 2004
7
Interleukin-12 p40 gene (IL12B) 3'-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. 57
12413772 2002
8
Characteristics, Associated Diseases, and Management of Gram-negative Toe-web Infection: A French Experience. 61
31502652 2019
9
Psoriasis Features in Patients with Inflammatory Bowel Disease. 61
30976349 2019
10
Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. 61
26959083 2016
11
Experiences From a Combined Dermatology and Rheumatology Clinic: A Retrospective Review. 61
27207352 2016
12
Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment. 61
25091090 2014
13
Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. 61
24251402 2014
14
Detection of DNA of Chlamydophila psittaci in subjects with psoriasis: a casual or a causal link? 61
22564212 2012
15
Prospective aetiological study of diaper dermatitis in the elderly. 61
17034522 2006
16
Analysis of 14-3-3sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. 61
12934112 2003
17
Cough sensitivity in atopic dermatitis. 61
12850122 2003
18
[Plasmosorption in combined therapy of psoriasis]. 61
9490341 1997
19
[A study of new patients at a dermatologic outpatient clinic]. 61
2919372 1989
20
Infantile psoriasis. 61
920679 1977

Variations for Psoriasis 11

Expression for Psoriasis 11

Search GEO for disease gene expression data for Psoriasis 11.

Pathways for Psoriasis 11

Pathways related to Psoriasis 11 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.08 IL23R IL17A IL12B
2
Show member pathways
12.03 IL23R IL17A IL12B
3 11.39 IL23R IL17A IL12B
4 11.34 IL23R IL17A
5
Show member pathways
11.28 IL17A IL12B
6
Show member pathways
11.1 IL23R IL17A IL12B
7 10.76 IL17A IL12B
8
Show member pathways
10.76 IL23R IL17A IL12B

GO Terms for Psoriasis 11

Cellular components related to Psoriasis 11 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.8 IL23R IL17A IL12B

Biological processes related to Psoriasis 11 according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.76 IL23R IL17A IL12B
2 positive regulation of tumor necrosis factor production GO:0032760 9.61 IL17A IL12B
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 IL23R IL12B
4 defense response to Gram-negative bacterium GO:0050829 9.61 IL23R IL17A IL12B
5 positive regulation of interferon-gamma production GO:0032729 9.6 IL23R IL12B
6 positive regulation of T cell proliferation GO:0042102 9.59 IL23R IL12B
7 positive regulation of defense response to virus by host GO:0002230 9.58 IL23R IL12B
8 positive regulation of activated T cell proliferation GO:0042104 9.57 IL23R IL12B
9 positive regulation of T cell mediated cytotoxicity GO:0001916 9.56 IL23R IL12B
10 negative regulation of interleukin-10 production GO:0032693 9.55 IL23R IL12B
11 positive regulation of interleukin-17 production GO:0032740 9.54 IL23R IL12B
12 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.52 IL23R IL12B
13 positive regulation of T-helper 1 type immune response GO:0002827 9.51 IL23R IL12B
14 positive regulation of memory T cell differentiation GO:0043382 9.49 IL23R IL12B
15 interleukin-23-mediated signaling pathway GO:0038155 9.48 IL23R IL12B
16 positive regulation of natural killer cell proliferation GO:0032819 9.46 IL23R IL12B
17 positive regulation of T-helper 17 type immune response GO:2000318 9.4 IL23R IL12B
18 positive regulation of activation of Janus kinase activity GO:0010536 9.37 IL23R IL12B
19 regulation of tyrosine phosphorylation of STAT protein GO:0042509 9.32 IL23R IL12B
20 positive regulation of NK T cell activation GO:0051135 9.26 IL23R IL12B
21 positive regulation of T-helper 17 cell lineage commitment GO:2000330 9.16 IL23R IL12B
22 positive regulation of interleukin-12 production GO:0032735 9.13 IL23R IL17A IL12B
23 positive regulation of osteoclast differentiation GO:0045672 8.8 IL23R IL17A IL12B

Molecular functions related to Psoriasis 11 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor activity GO:0004896 9.16 IL23R IL12B
2 cytokine binding GO:0019955 8.96 IL23R IL12B
3 interleukin-12 receptor binding GO:0005143 8.62 IL23R IL12B

Sources for Psoriasis 11

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....